Vertex: Long Term Buy Opportunity

By: Jason Napodano, CFA

Vertex Pharmaceuticals, Inc. (VRTX) represents an attractive long-term opportunity based on the potential blockbuster sales of telaprevir and its newly established position as the market leader for new HCV treatment options with the closing of the ViroChem deal in March 2009. Also, VX-770 for cystic fibrosis also looks very interesting. The financial situation is also solid with an estimated $700 million in cash predicted to be on hand at the end of the year.